Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment.
Age related macular degeneration
Choroidal neovascularization
Geographic atrophy
Optical coherence tomography
Vascular endothelial growth factor
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
received:
06
05
2020
accepted:
14
12
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
To study the enlargement rate of primary geographic atrophy (GA) before and after diagnosis of a secondary choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factor (VEGF) therapy. Five hundred twenty-two consecutive eyes with primary GA were screened for the development of a complicating secondary CNV. Geographic atrophy was measured on blue autofluorescence (BAF) by two readers and calculated into mean growth rate before and after CNV diagnosis. Ten eyes of six patients were included in the study (six study eyes with GA complicated by CNV, four GA only partner eyes). Follow-up was 1.42 ± 0.48 years before and 3.64 ± 2.73 years after CNV. There was no significant difference between mean growth rate before and after CNV (1.58 ± 0.99 vs. 1.39 ± 0.65 mm In this pilot study, primary GA enlargement did not seem to be influenced by a secondary CNV. No association between the intensity of anti-VEGF treatment and changes in atrophy enlargement rates were found. Further studies with larger sample sizes are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
To study the enlargement rate of primary geographic atrophy (GA) before and after diagnosis of a secondary choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factor (VEGF) therapy.
METHODS
METHODS
Five hundred twenty-two consecutive eyes with primary GA were screened for the development of a complicating secondary CNV. Geographic atrophy was measured on blue autofluorescence (BAF) by two readers and calculated into mean growth rate before and after CNV diagnosis.
RESULTS
RESULTS
Ten eyes of six patients were included in the study (six study eyes with GA complicated by CNV, four GA only partner eyes). Follow-up was 1.42 ± 0.48 years before and 3.64 ± 2.73 years after CNV. There was no significant difference between mean growth rate before and after CNV (1.58 ± 0.99 vs. 1.39 ± 0.65 mm
CONCLUSION
CONCLUSIONS
In this pilot study, primary GA enlargement did not seem to be influenced by a secondary CNV. No association between the intensity of anti-VEGF treatment and changes in atrophy enlargement rates were found. Further studies with larger sample sizes are warranted.
Identifiants
pubmed: 33402147
doi: 10.1186/s12886-020-01766-6
pii: 10.1186/s12886-020-01766-6
pmc: PMC7784328
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Références
Surv Ophthalmol. 2018 Nov - Dec;63(6):782-815
pubmed: 29859199
Ophthalmol Retina. 2017 Jan-Feb;1(1):34-41
pubmed: 28630947
Arq Bras Oftalmol. 2012 Jul-Aug;75(4):273-6
pubmed: 23258660
Br J Ophthalmol. 2006 Apr;90(4):442-6
pubmed: 16547324
Br J Ophthalmol. 1976 May;60(5):324-41
pubmed: 952802
Ophthalmology. 2014 Jan;121(1):150-161
pubmed: 24084496
Retina. 2013 Jan;33(1):13-22
pubmed: 22846802
Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):511-518
pubmed: 29374796
Ophthalmology. 2018 Jun;125(6):878-886
pubmed: 29477692
Ophthalmology. 2016 Aug;123(8):1751-1761
pubmed: 27156698
Lancet. 2018 Sep 29;392(10153):1147-1159
pubmed: 30303083
Sci Rep. 2020 May 15;10(1):8036
pubmed: 32415240
Retina. 2018 Sep;38(9):1743-1750
pubmed: 28691937
Ophthalmology. 2018 Feb;125(2):255-266
pubmed: 28964581
Lancet. 2013 Oct 12;382(9900):1258-67
pubmed: 23870813
Ophthalmology. 2014 May;121(5):1079-91
pubmed: 24433969
Acta Ophthalmol. 2016 Dec;94(8):e757-e764
pubmed: 27417506
Am J Ophthalmol. 2007 Mar;143(3):463-72
pubmed: 17239336
PLoS One. 2016 Feb 26;11(2):e0149978
pubmed: 26918864
Br J Ophthalmol. 2012 Dec;96(12):1479-83
pubmed: 23077229
Int J Retina Vitreous. 2015 Sep 3;1:15
pubmed: 27847608
Ophthalmologe. 2019 Sep;116(Suppl 2):25-218
pubmed: 31451897
Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6038-6045
pubmed: 29196768
Ophthalmology. 2018 Mar;125(3):369-390
pubmed: 29110945
Am J Ophthalmol. 2015 Jun;159(6):1100-1114.e1
pubmed: 25769245